title: [Testosterone replacement therapy for prostate cancer].
abstract: During the male 40s total testosterone levels decrease continuously. If clinical symptoms like decreasing libido, erectile dysfunction, osteoporosis, altered distribution of body fat, reduction in physical strength, or alterations in psychological mood are combined with a decreased serum testosterone level late-onset hypogonadism (LOH) is obvious. Before the substitution of testosterone is initiated, it is essential to exclude prostate cancer because the progress of prostate cancer depends on androgens. The question is now how to treat patients who suffer from androgen deficiency but have cured prostate cancer in their history? Concerning this there are only a few studies with a small number of patients which show that testosterone substitution therapy is possible without an increased risk for recurrence of prostate cancer. As long as the patient was cured it does not matter if he underwent a radical prostatectomy or brachytherapy. Absolutely necessary is that the patient is well informed about the therapy and regularly controlled during the therapy.
authors.affiliation: Klinik für Urologie, Kliniken Maria Hilf GmbH Mönchengladbach. angelika.kaminsky@mariahilf.de
authors.forename: A
authors.initials: A
authors.lastname: Kaminsky
authors.forename: H
authors.initials: H
authors.lastname: Sperling
mesh_terms: D015897:Comorbidity; D007172:Erectile Dysfunction / Q000453:epidemiology* / Q000517:prevention & control*; D020249:Hormone Replacement Therapy / Q000379:methods*; D006801:Humans; D007006:Hypogonadism / Q000453:epidemiology* / Q000517:prevention & control*; D015994:Incidence; D008297:Male; D011471:Prostatic Neoplasms / Q000453:epidemiology* / Q000628:therapy; D018570:Risk Assessment; D012307:Risk Factors; D013739:Testosterone / Q000008:administration & dosage*
chemical_list: D013739:Testosterone